AstraZeneca plc vs Barclays PLC — how do they compare? AstraZeneca plc trades at $158.15 (market cap $248.14B), while Barclays PLC trades at $28.01 (market cap $93.87B). The key difference: AstraZeneca plc is far larger — about 2.6× Barclays PLC's market cap, and Barclays PLC pays the higher dividend (2.19%). Which is the better fit depends on your goals.
| AZN | BCS | |
|---|---|---|
Market Cap | $248.14B | $93.87B |
Sector | Health | Financials |
52-Week High | $209.48 | $28.56 |
52-Week Low | $147.06 | $19.36 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 2.19% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Barclays PLC (BCS) trades at $27.98, up 0.18% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals, including a P/E of 10.68, P/B of 0.88, and net income margin of 25.51%, with Q2 2026 EPS beating estimates at $0.90. Recent news highlights a 17% profit jump in H1 2026 but also a securities class action investigation, creating mixed sentiment.
The outlook is cautiously optimistic, supported by earnings beats and a 68% analyst buy rating, but risks include cost pressures, legal scrutiny, and market volatility. Upside potential hinges on sustained profit growth and efficient cost management amid economic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →